Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...
Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...
Abstract: Analytical expressions that have been derived to calculate ac resistance and losses of magnetic devices at high frequencies have primarily used a one-dimensional approximation, and have used ...
Hosted on MSN
Expressing Spherical Unit Vectors in Cartesian Form
Physics and Python stuff. Most of the videos here are either adapted from class lectures or solving physics problems. I really like to use numerical calculations without all the fancy programming ...
CGAL version, kernels: 6.0.1, Cartesian, Extended_cartesian Python Version: Python 3.13.3 OpenCSG version: OpenCSG 1.8.1 Clipper2 version: 1.5.2 Manifold version: 3.2 ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Background: In my experience, given a customizer initialization the spinner usually increments the last digit. Eg, if testparam8=0.567; appears, the increment is 0.001. Problem: While the increment is ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...
Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial ...
Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25 Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results